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Rodenticides have historically been common agents in attempted suicides. As most rodenticides in 
the United States (U.S.) are superwarfarins, these ingestions are generally managed conservatively 
with close monitoring for coagulopathy, and if necessary, correction of any resulting coagulopathy. 
However, alternate forms of rodenticides are imported illegally into the U.S. and may be ingested 
either accidentally or in suicide attempts. We present an unusual case of poisoning by the illegally 
imported rodenticide, “Tres Pasitos.” The main ingredient of this rat poison is aldicarb, a potent 
carbamate pesticide that causes fulminant cholinergic crisis. This case is relevant and timely 
because carbamates and organophosphates are still used as insecticides and emergency physicians 
(EP) working in rural areas may have to evaluate and manage patients with these poisonings. As 
international travel and immigration have increased, so has the possibility of encountering patients 
who have ingested toxic substances from other countries. In addition, there has been increased 
concern about the possibility of acts of terrorism using chemical substances that cause cholinergic 
toxidromes.1,2 EPs must be able to recognize and manage these poisonings. This report describes 
the mechanism of action, clinical manifestations, laboratory evaluation and management of this type 
of poisoning. The pertinent medical literature on poisoning with aldicarb and similar substances is 
reviewed. [West J Emerg Med. 2010; 11(5): 524-527.]
CASE REPORT
A 29-year-old male presented to the emergency 
department (ED) after a suicide attempt by ingesting a large 
amount of rat poison, which according to emergency medical 
services (EMS) occurred just prior to arrival. Although EMS 
had been told that the patient had ingested a rat poison, the 
exact type of rodenticide was unknown. 
Upon arrival to the ED, the patient was diaphoretic and in 
moderate respiratory distress. His vital signs were as follows: 
temperature 36.0 0C, blood pressure 113/99 mm Hg, heart rate 
100 beats/minute, respiration rate 28 breaths/minute and 
oxygen saturation 88% on room air. 
On arrival he was awake but appeared to be confused and 
was not answering questions. Excessive secretions were noted. 
His neck was supple. He had respiratory distress with harsh 
breath sounds and rhonchi throughout both lung fields. He was 
tachycardic but had a regular rhythm. The abdomen was soft 
and non-tender with increased bowel sounds. The patient had 
urinated on himself. He was moving all extremities but had 
some muscle fasciculations. His skin was diaphoretic, but no 
rash or track marks were evident. He was confused, 
uncooperative and not speaking. The pupils were 2 mm and 
non-reactive to light. Cranial nerves otherwise appeared to be 
intact. It was difficult to assess his motor, sensory and 
cerebellar function because he was very uncooperative. 
Initially he was moving all his extremities. 
An initial bedside serum glucose analysis was 186 mg/dL. 
Other laboratory values were as follows: serum sodium 138 
mmol/L, potassium 2.9 mmol/L, chloride 101 mmol/L, 
bicarbonate 17 mmol/L, glucose 247 mg/dL, blood urea 
nitrogen 16 mg/dL, and creatinine 1.0 mg/dL. Complete blood 
count showed a white blood count of 12.8 × 103/µL with 58% 
neutrophils and 33% lymphocytes, hemoglobin level of 17.2 
g/dL and platelet count of 311,000 × 103/µL. Creatine kinase 
(CK) was 191 U/L (40-210) and CK-MB was 1.96 ng/ml 
(0.0-4.99) with a CK-MB index of 1% (0.0-2.49). Troponin I 
level was < 0.20 µg/L (0-2). His liver function tests showed 
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range. Urine analysis was normal and the urine toxicology 
screen was negative. The coagulation profile was normal. His 
electrocardiogram showed sinus tachycardia without ischemic 
changes or QRS or QT prolongation. A plasma cholinesterase 
level was drawn and sent to the laboratory. 
Fifteen minutes after being initially assessed, his 
condition rapidly deteriorated. He developed excessive 
salivation with large amounts of foamy white secretions, 
which continually spewed from his mouth, making it very 
difficult to keep his airway clear, even with mechanical 
suctioning. His oxygen saturation dropped into the low 80s, 
despite receiving high flow oxygen, and he was subsequently 
intubated. He was given 2 mg lorazepam intravenously (IV) 
prior to intubation to sedate him, and he was given another 2 
mg of it after he was intubated.
Based on the history and physical examination findings, 
which were consistent with an overdose of a cholinergic agent 
– probably an organophosphate or carbamate – the patient was 
given 2 mg of atropine IV, without any effect. He was then 
given another 2 mg IV every five minutes until his secretions 
were dry. He received a total of 16 mg of atropine IV in the 
ED. He was also given 1 gram of pralidoxime as an IV 
infusion over 30 minutes. He was hydrated with intravenous 
normal saline and his hypokalemia was corrected with 
potassium chloride.
When the staff realized that he had possibly taken an 
organophosphate, they double gloved and donned gowns and 
masks. All of the patient’s clothes were removed and 
discarded in plastic bags. He was washed with soap and water. 
After he was intubated, a nasogastric tube was inserted. He 
was lavaged and 50 grams of activated charcoal was 
administered down the nasogastric tube. None of the EMS or 
ED personnel developed any signs or symptoms of cholinergic 
poisoning. 
After intubation and treatment with atropine, pralidoxime 
and lorazepam, the patient’s respiratory status showed marked 
improvement. His oxygen saturation was 100%. He was 
admitted to the intensive care unit, where he did not require 
any further treatment with atropine or pralidoxime. He was 
weaned off the ventilator and extubated without difficulty on 
hospital day 4. He remained stable and was transferred to the 
medical floor where psychiatry was consulted. The patient was 
then admitted for attempting to suicide by ingesting a rat 
poison called “Tres Pasitos.” Its active ingredient is aldicarb, a 
very potent carbamate. His initial serum cholinesterase level 
was 103 units/ml (normal range 350-934), confirming the 
clinical diagnosis. This level was not repeated, because his 
clinical status greatly improved.
Eventually, he was cleared by psychiatry and discharged 
home with appointments for close follow up in the medical 
and psychiatry clinics. When the patient was seen in 
the medical clinic one week after discharge, he had no 
complaints, and no evidence of residual toxicity was found on 
examination. No further testing was performed.
DISCUSSION
Rodenticides come in many forms with a “superwarfarin” 
being a common type of rodenticide used in the U.S. In 2008, 
3.8% of the reports of poisonings were related to pesticides.3 
Other types of rodenticides are phosphides, phosphorus, 
strychnine, thallium, sodium fluoroacetate and cholinesterase 
inhibitors. Because cholinesterase inhibitors are no longer 
registered for rodenticidal use in the U.S., cholinergic 
symptoms and signs are uncommon in patients who report 
ingesting a rodencticide. Although illegal in the U.S., “Tres 
Pasitos” is bought and sold legally in certain Latin American 
countries and often imported unlawfully for sale in this 
country. The name “Tres Pasitos” (Spanish for “three little 
steps”) signifies the rapid lethal effects to mice, i.e. they can 
only take three little steps before dropping dead. Fatal 
intoxication with aldicarb, the active ingredient in “Tres 
Pasitos,” has been reported.4 Poisonings in the U.S. from 
“Tres Pasitos” has occurred between 1994-1997, when the 
New York City Poison Control Center was consulted 
regarding 25 patients who developed cholinergic toxicity after 
ingesting “Tres Pasitos.”5 Aldicarb is also used as a potent 
insecticide, and poisonings from exposure to this substance in 
agricultural areas and toxicity from the ingestion of aldicarb 
contaminated food have also been reported.6 
 With increases in immigration to the U.S. and 
international travel, it is reasonable to assume that there may 
be an increase in toxic substances brought to this country from 
other nations. Just as we should get a travel history in patients 
who present with fever or diarrhea, we should also consider 
the possibility of poisoning by an imported toxin when 
evaluating a patient with an unusual toxidrome. 
Concern now exists for the possibility of terrorist attacks 
using chemical agents. In fact, two incidents of attacks using 
the cholinesterase inhibitor nerve agent, sarin, have occurred 
in the recent past.7,8 The actions, clinical manifestations and 
management of poisoning by these agents are very similar to 
those of pesticides, such as organophosphates and carbamates 
like aldicarb. Therefore, it is very important that EPs be able 
to quickly recognize and manage cholinergic toxicity.
Aldicarb [2-methyl-2-(methylthio)-propionaldehyde 
O-(methylcarbamoyl) oxime], is a very potent carbamate.9 
Aldicarb is rapidly absorbed via the gastrointestinal tract.10 It 
binds to and inhibits human cholinesterase, which normally 
breaks down acetylcholine, resulting in an excess of 
aceylcholine and enhancement of its physiological effects at 
muscarinic, nicotinic and central nervous system (CNS) 
receptors causing a cholinergic crisis.11 It inhibits both red 
blood cell (RBC) cholinesterase and plasma 
pseudocholinestrase. Aldicarb has an LD50 (median lethal 
dose) in humans of 0.8 mg/kg. It is a toxic cholinergic agent 
that has caused many fatalities.12 It is especially toxic to the 
nervous system and is excreted completely in the urine within 
24 hours.
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 Clinical findings of toxicity reflect effects of excessive 
cholinergic stimulation at muscarinic, nicotinic and CNS 
receptors.13 Excessive stimulation of muscarinic receptors 
produces the “SLUDGE” toxidrome: salivation, lacrimation, 
urination, diarrhea, gastric secretions and emesis. It also 
produces miosis, and the “triple Bs”: bradycardia, 
bronchospasm and bronchorrhea. Bronchospasm and 
bronchorrea are especially dangerous, and patients can 
literally drown in their own secretions. In a case series of 
patients in Rio de Janeiro, who were poisoned by carbamates 
that were illegally used as rodenticides, all victims were noted 
to have at least two symptoms and/or signs of muscarinic 
toxicity described by the SLUDGE mnemonic.14
Aldicarb can also cause hyperactivity at nicotinic sites, 
especially at the skeletal muscle junctions, causing muscle 
fasciculations, weakness and paralysis that may lead to 
significant morbidity and mortality. Hyper-stimulation at the 
nicotinic receptors of the autonomic ganglia may cause 
tachycardia, mydriasis and hypertension, instead of 
bradycardia, miosis and hypotension that are seen when 
muscarinic stimulation at these sites predominates. 
Tachycardia may also be due to hypoxia. This is important to 
consider when both evaluating and treating these patients. 
When treating these patients with atropine, it is important to 
remember that the end point for atropinization is when 
secretions have been dried, not the presence of tachycardia or 
dilated pupils.15 
CNS toxicity often occurs with aldicarb and may be 
manifested as delirium, lethargy, coma or, less commonly, 
seizures. In one study that reviewed anti-cholinesterase 
poisonings, including aldicarb, the most common muscarinic 
symptom was diarrhea, the most common nicotinic symptom 
was muscle fasciculation and almost half of the patients had 
CNS depression with a Glasgow Coma Scale of less than 
eight.16 Therefore, the authors like to use a modified 
DUMBELS mnemonic (diarrhea, urination, miosis, muscle 
fasciculations, muscle weakness, mental status changes, 
bradycardia, bronchorrhea, bronchospasm, emesis, lacrimation 
and seizures) when evaluating patients for possible toxicity 
from aldicarb, other carbamates or organophosphates, as it 
describes the muscarinic, nicotinic and CNS effects of these 
toxins.
The diagnosis of poisoning with an anti-cholinesterase 
agent, such as aldicarb, in the ED must be made clinically 
based on the history and/or recognition of this toxidrome. 
Laboratory measurement of cholinesterase activity can help to 
eventually confirm the diagnosis. This can also be useful in 
following the course of this illness and for public health and 
epidemiologic purposes. Two types of cholinesterases, plasma 
(or pseudo-cholinesterase) and RBC cholinesterase, can be 
measured and both of their levels are decreased by anti-
cholinesterase toxins. However, although plasma 
cholinesterase is more easily performed by most laboratories, 
RBC cholinesterase is more accurate and correlates better 
with the severity of poisoning.17 
Because severe anti-cholinesterase poisoning has 
significant morbidity and mortality, emergency management 
should not be delayed once the diagnosis is suspected. The 
most important aspect of the treatment of aldicarb poisoning is 
to support the airway, breathing and circulation (ABC) of the 
patient. Special attention must be given to the airway and 
breathing, as these patients may become very hypoxic from 
excessive secretions, bronchorrhea, bronchospasm, weakness 
of respiratory muscles and CNS depression. In severe cases, 
the patient may require intubation. In these cases the patient 
should be paralyzed with non-depolarizing agents, such as 
vecuronium, if needed, rather than succinylcholine, which is 
metabolized by plasma cholinesterase and may cause 
prolonged paralysis.18
After stabilization of ABCs, specific therapy involves 
blockade of acetylcholine effects at both muscarinic and 
nicotinic receptors. Atropine provides inhibition at muscarinic 
receptors in both the CNS and the periphery. Very large doses 
are often needed. Therapy is begun with a dose of 2 mg in 
adults and 0.02 mg/kg (minimum dose of 0.1 mg) in children. 
This can then be repeated every three to five minutes until 
drying of pulmonary secretions has occurred. An alternative 
way of giving atropine in very severe cases is to start with 2 to 
5 mg IV in adults and 0.05 mg/kg in children and to double 
the dose every five minutes until secretions are dried up. As 
noted above, very large doses of atropine may be required, 
and the EP should not be afraid to use enough atropine to dry 
secretions. Atropine is not effective for reversing nicotinic 
effects. Patients can still develop respiratory failure from 
muscle paralysis, and these patients must be closely monitored 
and mechanically ventilated as needed.
The use of pralidoxime (2-PAM) in the treatment of 
poisoning by carbamates, including aldicarb, is somewhat 
controversial since, unlike organophosphates, the 
cholinesterase poisoned by a carbamate reactivates within a 
day. Therefore, pralidoxime, which markedly increases the 
regeneration of acetylcholinesterase and reverses both 
nicotinic and muscarinic toxicity, may not be needed, 
especially in mild to moderate poisonings. However, recent 
reports show that pralidoxime improves morbidity and 
mortality with severe poisonings from most carbamates.9,19 It 
makes the patient easier to manage by decreasing the atropine 
requirement and by treating nicotinic toxicity. Pralidoxime 
therapy should therefore not be withheld in a patient with 
significant cholinergic toxicity, because it is thought that the 
poisoning may be caused by a carbamate. Benzodiazepines, 
such as diazepam or lorazepam, can be used to control 
seizures and CNS agitation. 
It is also important to decontaminate patients who have 
aldicarb on their skin or clothing because it is rapidly 
absorbed through the skin. They should be totally exposed and 
Waseem et al.  Cholinergic CrisisWestern Journal of Emergency Medicine  527  Volume XI, no. 5  :  December 2010
Cholinergic Crisis   Waseem et al.
vigorously washed with soap and water. Anyone handling 
these patients or their clothing should be appropriately 
gowned and gloved. In the case of patients who have ingested 
the poison, like ours, and emesis has not occurred yet, gastric 
lavage with airway protection needs to be performed. 
Activated charcoal should also be administered through the 
nasogastric tube.
Although, if untreated or treated incorrectly, patients with 
poisoning from aldicarb can easily die, most patients do well 
if they are diagnosed rapidly and managed appropriately. The 
intermediate syndrome, muscle weakness and other 
neurological signs occurring after 24 hours, is rarely seen with 
aldicarb poisoning.20 
Our major limitation was that we were unable to obtain 
confirmatory laboratory or forensic evidence that the patient 
ingested aldicarb. We were not able to actually get samples 
of the “Tres Pasitos” that he took, nor did we measure 
aldicarb levels or levels of its metabolites. However, based 
on the history, his cholinergic toxidrome, his response to the 
appropriate therapy and very low serum cholinesterase level, 
it is conclusive that he took this poison. It must be emphasized 
that when possible, it is very helpful to get the “bottles” when 
evaluating a patient with a possible poisoning or overdose.
CONCLUSION
We presented the case of a patient who ingested a rat 
poison, “Tres Pasitos,” which was illegally imported into the 
U.S. This substance, which contains aldicarb, caused a life-
threatening cholinergic crisis. Due to increased immigration 
and international travel, it should be expected that similar 
cases will continue to be seen in our EDs. Because our 
patient’s cholinergic toxidrome was quickly recognized and 
correctly managed, he did very well.
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